Advertisement
Advertisement
FATE
Fate Therapeutics, Inc.
2.43
USDSponsored
+0.11
+4.74%
Oct 05, 15:58 UTC -4
Closed
After-Market
2.46
+0.03
+1.23%
FATE Earnings Reports
Positive Surprise Ratio
FATE beat 25 of 43 last estimates.
58%
Next Report
Date of Next Report
Oct 29, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.16M
/-$0.27
Implied change from Q2 26 (Revenue/ EPS)
-44.10%
/+8.00%
Implied change from Q3 25 (Revenue/ EPS)
-33.15%
/--
Fate Therapeutics, Inc. earnings per share and revenue
On Aug 13, 2026, FATE reported earnings of -0.25 USD per share (EPS) for Q2 26, beating the estimate of -0.27 USD, resulting in a 8.49% surprise. Revenue reached 2.08 million, compared to an expected 1.39 million, with a 49.45% difference. The market reacted with a -7.35% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 1.16 million USD, implying an increase of 8.00% EPS, and decrease of -44.10% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$0.07
Surprise
+2,158.06%
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
$0.00
Surprise
+99.70%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
FAQ
What were Fate Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Fate Therapeutics, Inc. reported EPS of -$0.25, beating estimates by 8.49%, and revenue of $2.08M, 49.45% above expectations.
How did the market react to Fate Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved down -7.35%, changed from $2.72 before the earnings release to $2.52 the day after.
When is Fate Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Oct 29, 2026.
What are the forecasts for Fate Therapeutics, Inc.'s next earnings report?
Based on 13
analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.27 and revenue of $1.16M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.